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Abstract
Approximately 20 % of familial Amyotrophic Lateral Sclerosis (ALS) is caused by mutations in superoxide dismutase
(SOD1), which leads to misfolding of the SOD1 protein, resulting in a toxic gain of function. Several conformation-
restricted antibodies have been generated that specifically recognize misfolded SOD1 protein, and have been used
as therapeutics in pre-clinical models. Misfolded SOD1 selectively associates with spinal cord mitochondria in SOD1
rodent models. Using the SOD1G93A rat model, we find that SOD1 conformational specific antibodies AMF7-63 and
DSE2-3H1 labeled a fibrillar network concentrated in the anterior horn; while A5C3, B8H10, C4F6 and D3H5 labeled
motor neurons as well as puncta in the neuropil. There is a time-dependent accumulation of misfolded SOD1 at
the surface of spinal cord mitochondria with AMF7-63-labeled mitochondria having increased volume in contrast to
a mitochondrial subset labeled with B8H10. In spinal cord homogenates and isolated mitochondria, AMF7-63, DSE2-
3H1 and B8H10 detect misfolded SOD1 aggregates. SOD1 that lacks its metal cofactors has an increased affinity for
naïve mitochondria and misfolded SOD1 antibodies B8H10 and DSE2-3H1 readily detect demetalated mutant and
wild-type SOD1. Together, these data suggest that multiple non-native species of misfolded SOD1 may exist, some
of which are associated with mitochondrial damage. Conformational antibodies are invaluable tools to identify and
characterize the variation in misfolded SOD1 species with regards to biochemical characteristics and toxicity. This
information is highly relevant to the further development of these reagents as therapeutics.
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Introduction
The defining feature of the neurodegenerative disease
Amyotrophic Lateral Sclerosis (ALS) is the loss of motor
neurons in the cortex, brain stem and spinal cord [1]. Loss
of motor neurons leads to denervation resulting in muscle
weakness, atrophy and eventual paralysis. Despite identifi-
cation of the first gene linked to familial ALS (FALS),
Superoxide Dismutase 1 (SOD1) [2] over twenty years
ago, and the discovery of many more ALS genes since, the
causes of motor neuron degeneration remain unknown.
Mutations in SOD1 account for 15 to 20 % of all FALS
cases, and approximately 3 % of sporadic ALS (SALS) cases
[3]. SOD1 mutations universally lead to conformation
changes within the native protein structure, resulting in
the acquisition of an elusive toxic function [4]. Several anti-
bodies have been developed to specifically target these
altered conformations, which are collectively referred to as
misfolded SOD1 (reviewed in [5, 6]). Recombinant
SOD1G93A protein lacking its metals (apo), including the
structure stabilizing zinc cofactor, was used for
immunization which led to the generation of a heteroge-
neous pool of antibodies with different affinities and re-
activity to distinct epitopes located on one or more of the
SOD1G93A protein conformers. These antibodies were sub-
sequently clonally expanded to monoclonal antibodies
named as A5C3, B8H10, C4F6, and D3H5 [7, 8]. Other
antibodies, such as DSE2-3H1, SEDI, USOD, and a series
of polyclonal antibodies produced by Forsberg and col-
leagues, were produced via immunization with peptides
comprised of amino acids that are normally inaccessible in
the well folded protein [9–11]. All of these antibodies
recognize epitopes that are exposed only when SOD1
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adopts a non-native conformation induced either by muta-
tion, loss of its zinc cofactor, and/or oxidation. While many
of these were developed with the intent to be potential
therapeutics, these reagents have also become valuable
tools with which to track the toxic forms of SOD1. Mis-
folded SOD1 is detected predominantly within the motor
neurons of ALS animal models [8, 11–14]. In humans,
various antibodies report on misfolded SOD1 in neurons
of FALS patients as well as SALS patients, although this
latter finding remains controversial [7, 9, 15, 16]. In pre-
clinical research using mutant SOD1 animals, it is now
appreciated that reducing misfolded SOD1 levels via
immunization significantly increases survival [8, 17]. This
provides additional support that misfolded SOD1 lies at
the root of SOD1-mediated ALS [8, 17].
Despite consensus in the field that misfolded SOD1 is
central to disease pathogenesis, it remains unknown
how misfolded SOD1 causes motor neuron death. Mis-
folded SOD1 has been implicated in the induction of
endoplasmic reticulum (ER) stress [12, 18], defective
axonal transport [7], alteration of motor neuron excitabil-
ity [19], and mitochondrial dysfunction [11, 13, 14, 20] in
SOD1-mediated ALS disease models. Multiple aspects of
mitochondrial physiology are disrupted in mutant SOD1
cell culture and animal models including morphology
[21–23], adenosine triphosphate (ATP) generation [24],
calcium handling [25], axonal transport [26] and protein
import [27]. Interestingly, misfolded SOD1 directly associ-
ates with mitochondria derived from affected, but not un-
affected tissues [11]. The selective association of misfolded
SOD1 to spinal cord mitochondria has just recently been
attributed to a lack of the putative chaperone macrophage
migration inhibitory factor (MIF) in this tissue, and more
specifically motor neurons [28].
Recent evidence suggests that multiple non-native/
misfolded SOD1 species may exist [29–31]. Consistent
with this concept, we have previously reported that the
B8H10 antibody detects misfolded SOD1 in both cyto-
solic and mitochondrial fractions prepared from
SOD1G93A spinal cords while the C4F6 antibody exclu-
sively detects cytosolic misfolded SOD1 [13]. Other
work in cultured cells made to overexpress mutant
SOD1 indicates that the C4F6 antibody recognizes sol-
uble mutant protein, whereas SEDI preferentially detects
mutant SOD1 within inclusions [31]. Additionally, a
series of polyclonal SOD1 peptide-specific antibodies
identify two different forms of SOD1 aggregates (or
“strains”) in mutant SOD1 mice based on epitope acces-
sibility, with one such aggregate-type/strain correlating
with an earlier age of onset [30]. Together these data
suggest that multiple forms of misfolded SOD1 are
possible.
We hypothesized that if more than one form of mis-
folded SOD1 exists, there may be conformer-specific
differences in localization, potency and/or pathomecha-
nistic consequences. To this end, we have employed a
panel of misfolded SOD1-specific antibodies, to evaluate
misfolded SOD1 localization, ability to induce mitochon-
drial toxicity and incorporation into aggregates. Herein,
we report that the misfolded SOD1-specific antibody
DSE2-3H1 labels motor neurons and robustly detects fi-
brils in the anterior horn of SOD1G93A spinal cords, a
finding that is confirmed by a second independent anti-
body raised against the same peptide immunogen
(AMF7-63). Other misfolded SOD1-specific antibodies,
A5C3, B8H10, C4F6 and D3H5 antibodies label predom-
inantly to motor neurons and numerous neuropil
puncta. Despite their different labeling patterns within
the spinal cord, both B8H10 and AMF7-63 antibodies
immunolabel spinal cord mitochondria in a time-
dependent manner. However, the presence of AMF7-63-
reactive misfolded SOD1 at mitochondria correlates with
a more severe dysregulation of mitochondrial volume




SOD1G93A and SOD1WT transgenic rats have been previ-
ously described [32, 33]. Non-transgenic littermates were
used in some experiments. Early symptomatic is defined
as animals that have a noticeable gait defect, hopping or
limping, typically involving only one limb. Both male
and female rats were used. Animals were treated in strict
adherence to approved protocols from the CRCHUM In-
stitutional Committee for the Protection of Animals and
the Canadian Council on Animal Care (CCAC).
Antibodies
Rabbit anti-Cu/Zn SOD (Enzo Life Sciences), rabbit anti-
SOD1 (Cell Signaling), mouse anti-VDAC1 (Calbiochem),
mouse anti-Actin (MP Biomedicals), were used for immu-
noblots. Anti-misfolded SOD1 mouse monoclonal anti-
bodies D3H5 (1:250, generously provided by Dr. J-P Julien),
A5C3 (1:50), B8H10 (1:250) and C4F6 (1:250) (Medimabs),
DSE2-3H1 (1:1000), rabbit monoclonal antibody AMF7-63
(1:1500) and rabbit polyclonal antibody SEDI (1:100, gener-
ously provided by Dr. J. Robertson) were used for immuno-
blotting, immunofluorescence and flow cytometry. Mouse
and rabbit IgG (Jackson ImmunoResearch Labs) and mouse
anti-IgG1 (BD Biosciences) were used as controls. Goat
anti-mouse allophycocyanin-conjugated (BD Pharmingen),
goat anti-rabbit PE (eBioscience) and goat anti-rabbit PE-
Cy7-conjugated (Santa Cruz) secondary antibodies were
used for flow cytometry studies. For immunofluorescence,
goat anti-ChAT (1:100; Millipore), mouse anti-SMI32
(1:2000; Covance), mouse anti-SMI31 (1:2000; Covance)
and mouse anti-MAP2 (1:500; Sigma) were used.
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Flow cytometry of isolated mitochondria
Spinal cord and liver mitochondria were isolated from
mice and rats [11], and prepared for analysis by flow cy-
tometry, as previously described [13, 34].
Immunoprecipitation and immunoblotting
Isolated mitochondria were solubilized and immunopre-
cipitated as previously described [11]. Briefly, 50 μg of
mitochondria were incubated with 15 μL Protein G mag-
netic beads (Invitrogen), overnight at 4 °C with rotation.
Protein G beads were previously incubated with mis-
folded SOD1-specific antibody. Immunoprecipitated
proteins were eluted from the beads in 2.5× Laemmli
buffer and electrophoresed on 15 % Tris-Glycine gels,
and subsequently transferred to nitrocellulose.
Immunofluorescence
Sections were labeled with anti-misfolded SOD1 anti-
bodies, as previously described [13]. Briefly, sections
were washed 10 min at room temperature in PBS, then
permeabilized for 10 min at room temperature in PBS
with 0.4 % TX-100. Sections were blocked with 2 %
normal donkey serum (Sigma), 2 % bovine serum albu-
min (Sigma), in 0.4 % TX-100/PBS for 1 h at room
temperature. Primary antibodies were incubated over-
night at 4 °C in blocking solution. Appropriate second-
ary antibodies were added in blocking solution for 1 h at
room temperature. Sections were mounted using Pro-
Long antifade reagent (Invitrogen). Immunofluorescent
images were captured by confocal microscopy (Leica
SP5; 20× and 40× objective, 1.7 NA) and processed with
Leica LAS AF software and/or PhotoshopCS4 (Adobe).
Filter-trap assay
20 μg of spinal cord homogenates or isolated spinal cord
mitochondria in PBS were filtered through a 0.22 μm
cellulose acetate membrane (GE Healthcare) using the
Bio-Dot Microfiltration Apparatus (Bio-Rad). Wells were
washed twice with PBS, the membrane was removed
from the apparatus and then blocked 1 h at room
temperature and immunoblotted with misfolded SOD1-
specific antibodies. Mitochondria for these experiments
were prepared by floating upwards to their buoyant
density so as to avoid possible co-sedimentation of ag-
gregates, as previously described [11].
Dot blot of recombinant SOD1 protein
1 μg of recombinant SOD1 protein, produced as previ-
ously described [35–37], in TBS (20 mM Tris, 500 mM
NaCl, 1 mM EDTA pH 7.5) was spotted onto nitrocellu-
lose membrane (BioRad) using the Bio-Dot Microfiltra-
tion Apparatus (Bio-Rad). Wells were washed twice with
TBS, and the membrane was removed from the appar-
atus and blocked in TBS-T (as above plus 0.05 %
Tween-20) with 1 % bovine serum albumin (BSA) for
30 min at room temperature, and immunoblotted with
misfolded SOD1 antibodies. Primary and secondary anti-
bodies were incubated in blocking buffer. For non-native
samples, 5 % v/v BME, and 0.5 % v/v SDS was added,
and samples were heat denatured by incubation for
5 min at 95 °C.
In vitro mitochondrial binding assay
50 μg of isolated spinal cord mitochondria (2 μg/μL)
from non-transgenic rats were incubated with 3 μM
baculovirus-produced SOD1WT and SOD1G93A recom-
binant protein, purified as previously described [38], for
20 min at 37 °C in HB Buffer (210 mM Mannitol,
70 mM Sucrose, 10 mM Tris pH 7.5, 1 mM EDTA) [38].
Mitochondria were washed once with HB buffer and
then re-suspended in HB and 4× Laemmli sample buffer
and subjected to SDS-PAGE and immunoblotted with
an antibody to human SOD1 (Cell Signaling). To deter-
mine if modification of SOD1 structure would alter its
binding to the mitochondrial surface, the protein was in-
cubated with 5.5 mM EDTA or 10 mM hydrogen perox-
ide in PBS overnight at 4 °C or room temperature,
respectively, with protease inhibitors (Roche). EDTA and
hydrogen peroxide were removed and replaced by PBS
by dialysis with Slide-A-Lyzer Mini dialysis devices
(Pierce). Untreated samples were treated equivalently.
Statistics
Two-way ANOVA was used to determine the interaction
between groups and time for percentage of misfolded
SOD1+ mitochondrial subpopulations over time and differ-
ences in AMF7-63+, B8H10+, and negative mitochondrial
subpopulations over time. Sidak’s multiple comparison test
was used to determine differences between misfolded
SOD1+ groups. One-way ANOVA was used to determine
differences in AMF7-63+, AMF7-63+B8H10+ and B8H10+
subpopulations. * P < 0.05, ** P < 0.01 *** P < 0.001,
**** P < 0.0001. All analyses was done with GraphPad
Prism software.
Results
Misfolded SOD1 specific antibodies DSE2-3H1 and AMF7-
63 detect fibrils in the spinal cord of SOD1G93A rats
To evaluate whether multiple antibodies targeted to
non-native/misfolded conformations of SOD1 yielded a
universal localization under similar conditions, lumbar
sections of symptomatic SOD1G93A rat spinal cords were
labeled with a panel of misfolded SOD1 specific anti-
bodies. In symptomatic SOD1G93A rats, all of the mis-
folded SOD1-specific antibodies tested (A5C3, B8H10,
C4F6, D3H5, DSE2-3H1, and AMF7-63) labeled motor
neurons as marked by choline acetyltransferase (ChAT)
(Fig. 1a). Antibodies DSE2-3H1 (mouse monoclonal)
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and AMF7-63 (rabbit monoclonal) were raised against
the same epitope located in the electrostatic loop (amino
acids 125DDLGKGGNEESTKTGNAG142) of SOD1
which is normally inaccessible in the well-folded SOD1
structure [11]. In symptomatic animals, both antibodies
intensely labeled the anterior horn albeit with varying af-
finities, with AMF7-63 demonstrating a more intense la-
beling (Fig. 1a). This is consistent with a 103-fold
enhanced affinity for the immunogenic peptide (N.
Cashman, unpublished data). The labeling resembled a
network of fibril-like structures, with some motor
neuron soma being obviously labeled. In general, the fi-
brillar pattern detected by DSE2-3H1 and AMF7-63 was
so robust, it was often difficult to discern individual
motor neurons. These two antibodies also revealed a fi-
brillar network in pre-symptomatic animals (14 and
15 weeks old, Fig. 1b). In contrast, fibrils were only occa-
sionally detected in sections labeled with misfolded
SOD1 antibodies A5C3, B8H10 and C4F6, but not
D3H5, in pre-symptomatic as well as symptomatic ani-
mals (data not shown). Instead, we noted that A5C3,
B8H10, C4F6 and D3H5 antibodies homogenously la-
beled motor neuron somata, and this was accompanied
by numerous small puncta observed throughout the
neuropil (Fig. 1a). As expected, none of the antibodies
yielded a signal in lumbar spinal cords of age-matched
rats expressing comparable levels of human wild type
SOD1 (SOD1WT), thereby confirming antibody specifi-
city, nor was there non-specific labeling in IgG controls
or sections stained with secondary antibody alone
(Additional file 1: Figure S1A, B). AMF7-63-reactive
misfolded SOD1 fibrils could be localized to different
motor neuron subcompartments including the soma,
dendrites (SMI32, MAP2) and axons (SMI31) (Fig. 1c).
These initial studies indicate that misfolded SOD1-
specific antibodies can be broadly considered as two dis-
tinct groups: A5C3, B8H10, C4F6, and D3H5 which
label motor neurons and numerous puncta throughout
the neuropil; and AMF7-63 and DSE2-3H1 which also
label motor neurons but also intensely reveal fibril-like
structures. Based on these spatial considerations, these
data suggest that more than one type of misfolded
SOD1 species exists in vivo.
To determine if these seemingly different misfolded
SOD1 conformations could co-exist within the same
motor neuron, spinal cord sections were co-labeled with
AMF7-63 and B8H10. A partial co-localization of these
two antibodies within ChAT-positive motor neurons was
frequently observed (Fig. 1d), suggesting that these anti-
bodies recognize apparently distinct non-native SOD1
species within the same neurons. In addition, we ob-
served neurons that labeled with AMF7-63 uniquely (ie.
void of B8H10), and vice versa.
AMF7-63 antibody detects misfolded SOD1G93A at the
mitochondrial surface
Several misfolded SOD1-specific antibodies (DSE2-3H1,
A5C3, B8H10, SEDI) recognize misfolded SOD1 protein
deposited on the cytoplasmic face of the mitochondrial
outer membrane [10, 11, 13, 14, 20]. However, this is
not a universally shared feature of misfolded SOD1 as
conformers recognized by C4F6 are primarily cytosolic
and exhibit little to no mitochondrial association [13].
We sought to determine if AMF7-63-reactive misfolded
SOD1 also associates with mitochondria. Misfolded
SOD1-specific antibodies A5C3, B8H10, DSE2-3H1 and
AMF7-63 were used to immunoprecipitate misfolded
SOD1 from spinal cord mitochondria isolated from
symptomatic SOD1G93A animals (Fig. 2a). As previously
published, B8H10 and DSE2-3H1-reactive SOD1 were
robustly detected in mitochondrial fractions [11, 13, 28]
(Fig. 2a). AMF7-63 detected similar amounts of mis-
folded SOD1 (Fig. 2a). A5C3, which we have previously
demonstrated to label misfolded SOD1 on distal axonal
mitochondria [11] also detected misfolded SOD1 within
mitochondrial fractions, but to a lesser extent than the
other antibodies (Fig. 2a). While a non-specific band
migrating just above SOD1 was detected when the
AMF7-63 antibody was used for immunoprecipitation,
the specificity of the AMF7-63 antibody for misfolded
SOD1 was confirmed by immunoprecipitation of spinal
cord homogenates and isolated mitochondria from
symptomatic SOD1G93A rats as well as age-matched
SOD1WT rats. As expected, AMF7-63 immunoprecipi-
tated misfolded SOD1 exclusively from SOD1G93A rat
spinal cord homogenates and mitochondria, but not
similar preparations from livers or SOD1WT tissue
(Additional file 2: Figure S2).
We wondered if the presence of AMF7-63-reactive mis-
folded SOD1 conformer negatively impacted mitochondrial
(See figure on previous page.)
Fig. 1 Misfolded SOD1-specific antibodies have distinct labeling patterns in SOD1G93A rat spinal cords. Immunohistochemistry for misfolded SOD1
in SOD1G93A lumbar spinal cords. a Lumbar sections of a symptomatic SOD1G93A rat were stained with misfolded SOD1 specific antibody A5C3
(green) and co-labeled with ChAT (blue). Additional representative images of B8H10, C4F6, D3H5, DSE2-3H1 and AMF7-63 are also shown. b The
AMF7-63 antibody detects fibrils in pre-symptomatic, 14 and 15 week SOD1G93A rat spinal cords. c Symptomatic SOD1G93A rat spinal cord was
labeled with AMF7-63 (green) and SMI32 (red), SMI31 (red), or MAP2 (red). d Lumbar sections labeled with misfolded SOD1 antibodies AMF7-63
(blue), B8H10 (green), and co-labeled with ChAT (red). Two to three animals of each genotype were analyzed. Scale bar = 100 μm for (a, b and d)
and 25 μm for (c)
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function. To this end, we employed surface-labeling with
the misfolded SOD1-specific antibodies AMF7-63 and
B8H10 and subsequent flow cytometric detection of iso-
lated spinal cord mitochondria [34]. Using early symptom-
atic SOD1G93A rats, we established that AMF7-63
preferentially detected misfolded SOD1 on isolated spinal
cord mitochondria compared to liver, a tissue that is un-
affected in ALS (Fig. 2b). Significantly more individual
spinal cord mitochondria (as marked by the indicator dye
MitoTracker Green, MTG) from SOD1G93A rats labeled for
Fig. 2 B8H10 and AMF7-63 reactive misfolded SOD1 is present in SOD1G93A spinal mitochondrial fractions. a Immunoprecipitation for misfolded
SOD1 in isolated SOD1G93A mitochondria with A5C3, B8H10, DSE2 3H1 and AMF7-63. Mouse (mIgG) and rabbit IgG (rbIgG) serve as controls. Input
is 10 μg isolated mitochondria. Upper bands and lower bands correspond to human (hSOD1) and rat (rSOD1) SOD1, respectively. Immunoprecipitation
with AMF7-63 resulted in a non-specific band (*) just above human SOD1, regardless of misfolded SOD1 status. Experiment shown is representative of
three independent trials. b Immunolabeling of isolated spinal cord and liver mitochondria with misfolded SOD1-specific antibody AMF7-
63 from symptomatic SOD1G93A rats and controls (aged matched SOD1WT and non-transgenic rats) by flow cytometry. Misfolded SOD1
positive labeling is determined by comparing to isotype control (rabbit IgG, dotplots in first column) of SOD1G93A sample. Percentage of
misfolded SOD1+ events is shown for each tissue and genotype in a representative sample. c Quantification of AMF7-63+ events in spinal
cord (green circle) or liver (black square) of symptomatic SOD1G93A rats, and age- matched SOD1WT as well as non-transgenic rats. Data
are represented as percent of misfolded AMF7-63+ mitochondria, each dot represents one animal, n = 4 animals per genotype per tissue.
d Comparison of spinal cord mitochondrial labeling positive for AMF7-63 (green, circle) or B8H10 (blue, square) in pre-symptomatic (10 and 14 weeks)
and symptomatic SOD1G93A rats by flow cytometry. Data are represented as percentage of misfolded SOD1+ mitochondria, each dot represents one
animal, (mean), n = 4–11 animals. ** P < 0.01. *** P < 0.001
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AMF7-63 (6.6 ± 1.9 %) compared to SOD1WT (0.1 ±
0.03 %) and non-transgenic (0.2 ± 0.03 %) animals
(SOD1G93A vs, SOD1WT, non-transgenic: P < 0.001) (Fig. 2b,
c). As expected, AMF7-63-reactive misfolded SOD1 was
not detected (ie. below 1 %) on liver mitochondria from
any group, confirming specificity of misfolded SOD1 for af-
fected tissues (SOD1G93A: 0.1 ± 0.1 %; SOD1WT: 0.3 ±
0.02 %; non-transgenic: 0.1 ± 0.2 %, n = 4 animals per geno-
type) (Fig. 2c). Similarly, and consistent with our previous
work [13], B8H10+ mitochondria were robustly detected in
mitochondrial preparations from symptomatic SOD1G93A
spinal cords (6.1 ± 0.4 %) but not SOD1WT (0.4 ± 0.2 %) or
non-transgenic cords (0.4 ± 0.1 %) (SOD1G93A vs, SOD1WT,
non-transgenic: P < 0.0001, n = 3 animals per genotype)
(Additional file 3: Figure S3A, B). There was no substantial
B8H10 labeling of liver mitochondria in any animal model
tested (Additional file 3: Figure S3A, B).
At an early symptomatic stage, surface labeling of iso-
lated spinal cord mitochondria demonstrated that both
AMF7-63 and B8H10 antibodies detected misfolded
SOD1 at the cytoplasmic face of the mitochondrial outer
membrane (Fig. 2d). Thus, we asked whether there was
a temporal difference in the accumulation of these two
conformers. Spinal cord mitochondria from 10 week old,
14 week old and early symptomatic SOD1G93A rats were
processed for labeling with B8H10 and AMF7-63. While
no mitochondrial signal for either antibody was detected
at 10 weeks, comparable labeling was detected in mito-
chondria from 14 week animals (AMF7-63+: 1.5 ± 0.6 %;
B8H10+: 2.1 ± 0.5 %). Higher proportions of mitochon-
dria labeled for misfolded SOD1 at the early symptom-
atic stage compared to the 10 and 14 week groups,
demonstrating a significant age-dependent accumulation
of each misfolded SOD1 conformer at the mitochondrial
surface (P < 0.0001). Comparison of the relative amounts
of AMF7-63+ (5.2 ± 1.1 %) and B8H10+ (6.9 ± 0.6 %) sub-
populations yielded no significant differences (Fig. 2d).
Collectively, these data would suggest that there is no
preferential temporal accumulation of these two forms
of non-native SOD1 conformers at the mitochondrial
surface.
Given these latter data, one could argue that the anti-
bodies are detecting the same conformer in vivo. Thus,
to address this, we analyzed our data to determine if it
was possible to detect B8H10-labeled mitochondria void
of AMF7-63 labeling, and vice versa. By simultaneously
immunolabeling isolated mitochondria with both
AMF7-63 and B8H10, we were able to discern four dis-
tinct mitochondrial subpopulations: i) double negative
(AMF7-63−B8H10−); ii) AMF7-63 only (AMF7-63
+B8H10−) 2.4 % in the illustrated example; iii) B8H10
only (AMF7-63−B8H10+), 2.9 % in the illustrated ex-
ample; and iv) double positive (AMF7-63+B8H10+),
5.4 % in the illustrated example (Fig. 3a). Therefore, the
total AMF7-63+ subpopulation (7.8 %) consists of both
B8H10+ (5.4 %) and B8H10− mitochondria (2.4 %). That
a proportion of mitochondria label positive with both
misfolded SOD1 antibodies, while others label for only
one conformer, suggests that AMF7-63 and B8H10
recognize distinct misfolded SOD1 species.
From 14 weeks to the early symptomatic stage, there
was a significant time dependent increase in the percent-
age of misfolded SOD1 B8H10-labeled mitochondria
(P < 0.01) (Fig. 3b). The relative amounts of the three
subpopulations with surface-bound misfolded SOD1 re-
vealed no significant differences between them at 14 weeks.
Interestingly, between 14 weeks and the early symptom-
atic stage, the proportion of AMF7-63+B8H10+ and
AMF7-63−B8H10+ mitochondrial subpopulations nearly
doubled, whereas the AMF7-63+ B8H10− subpopulation
remained roughly constant (Fig. 3b). At the latter
time point, there is a significantly higher percentage
of AMF7-63−B8H10+ than AMF7-63+B8H10− mito-
chondria (P < 0.01) (Fig. 3b). These data suggest there
is either preferential removal of the AMF7-63 only sub-
population or disturbed removal/enhanced accumulation
of B8H10 only mitochondria.
Volume dyshomeostasis and superoxide production is
enhanced in mitochondria with surface-bound AMF7-63-
reactive SOD1
A distinct advantage of the flow cytometry-based
method to detect mitochondrially-associated misfolded
SOD1 is that it permits the simultaneous use of fluores-
cent indicator dyes to report on mitochondrial functions.
Since a difference in the timing of mitochondrial associ-
ation between AMF7-63+ and B8H10+ mitochondria was
not detected (Fig. 2d), we hypothesized that perhaps they
may exhibit variable toxicity towards mitochondria.
Thus, we evaluated select aspects of mitochondrial func-
tion in the AMF7-63+ subpopulation. Mitochondrial
size/volume was assessed by flow cytometry on the basis
of the intensity of forward light scatter (FSC) of individ-
ual mitochondria [39, 40]. Quantification of the FSC
normalized to the total population indicate that the total
mitochondrial subset bearing AMF7-63 reactive mis-
folded SOD1 from 14 week and early symptomatic
SOD1G93A animals were significantly larger than non-
coated mitochondria (P < 0.001) (Fig. 4a). Intriguingly,
the AMF7-63+ subpopulation was also significantly larger
than the B8H10+ subpopulation (regardless of AMF7-63
status) when animals began exhibiting early symptoms
(P < 0.0001) (Fig. 4a).
Mitotracker Green (MTG) can be used not only to
identify mitochondria, but also to report on mitochon-
drial volume. Specifically, dye uptake measured by the
delta mean fluorescence intensity (ΔMFI) correlates with
mitochondrial volume as the dye accumulates within
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mitochondria independent of the mitochondrial trans-
membrane potential [41]. In agreement with our FSC
data, AMF7-63+ and B8H10+ subpopulations have a sig-
nificantly higher ΔMFI compared to uncoated mito-
chondria at both time points (AMF7-63+, P < 0.0001;
B8H10+, P < 0.01), with AMF7-63+ mitochondria taking
up more dye compared to B8H10+ mitochondria when
animals are in the early symptomatic stage (P < 0.0001)
(Fig. 4b). Together, these data indicate that the association
of AMF7-63-reactive misfolded SOD1 conformers with
the mitochondrial surface correlates with enlarged
mitochondria.
Superoxide is produced as a natural by-product of oxi-
dative phosphorylation [42]. We evaluated the levels of
mitochondrial superoxide produced by the AMF7-63+
and B8H10+ subpopulations using MitoSOX Red, a
mitochondria-specific superoxide indicator [43, 44].
Following normalization for size differences, misfolded
SOD1+ mitochondrial subpopulations produced signifi-











Fig. 3 Four distinct mitochondrial subpopulations revealed by simultaneously immunolabeling with AMF7-63 and B8H10 misfolded SOD1-specific
antibodies. a Flow cytometric analysis of isolated spinal cord mitochondria from symptomatic SOD1G93A animals labeled with AMF7-63 and B8H10.
Analysis only includes events previously gated for MTG staining (MTG+). Percentage of misfolded SOD1+ events is shown for each subpopulation in a
representative experiment. b Quantification of AMF7-63+B8H10− (green, circle), AMF7-63+B8H10+ (black, square) and B8H10+ AMF7-63− (blue, triangle)
mitochondrial subpopulations from spinal cords of 14 week and early symptomatic SOD1G93A rats. Data are represented as percent of misfolded SOD1+
mitochondria (mean), n= 4–11 animals per subpopulation. ** P < 0.01



































































































Fig. 4 Presence of AMF7-63 reactive misfolded SOD1 at the mitochondrial surface coincides with increased mitochondrial volume. Flow cytometric
analysis of isolated spinal cord mitochondria from 14 week and early symptomatic SOD1G93A rats labeled with misfolded SOD1 specific antibodies
AMF7-63 and B8H10. Analysis includes only events previously gated for MTG staining (MTG+). a Quantification of the geometric mean of FSC of AMF7-
63+ (green) B8H10+ (blue) and negative (white) mitochondrial subpopulations relative to total population in 14 week and symptomatic SOD1G93A
rats. b Quantification of delta mean fluorescence intensity (ΔMFI) of MTG staining of mitochondrial sub-populations relative to total population.
c Quantification of percentage of MitoSOX+ mitochondria from mitochondrial subpopulations relative to total population. Each subpopulation was
normalized for MTG staining. d Quantification of ΔMFI of TMRM staining of mitochondrial subpopulations relative to total population and normalized
to size/MTG. n = 4–5 animals per time point. Not significant (ns), * P < 0.05, ** P < 0.01, **** P < 0.0001
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misfolded SOD1− subpopulation at both 14 weeks and
when animals began to exhibit symptoms (P <0.05). Fur-
ther comparison revealed that while the AMF7-63+ and
B8H10+ subpopulations were not significantly different
from each other, the AMF7-63+ subpopulation was sig-
nificantly increased compared to the unlabeled subpopu-
lations at the early symptomatic stage (P < 0.05, Fig. 4c).
These changes were independent of mitochondrial trans-
membrane potential (ΔΨm) which was unchanged be-
tween subpopulations (Fig. 4d). Taken together, these
data suggest that there could be variable mitochondrial
damage associated with different conformers of mis-
folded SOD1, given that AMF7-63-reactive misfolded
SOD1 is associated with more severe deregulation of
mitochondrial volume homeostasis, while superoxide
production is equivalent to B8H10-coated mitochondria.
Misfolded SOD1 conformers are aggregated on
mitochondria
Given that B8H10 and AMF7-63-reactive misfolded
SOD1 disturbed mitochondrial volume to varying de-
grees, we speculated this might be attributed to differ-
ences in biochemical properties. Certain misfolded
SOD1-specific antibodies are reported to detect cyto-
plasmic aggregates/inclusions [30, 31], but whether mis-
folded SOD1 aggregates at/on mitochondria remains
unknown. Therefore, we examined the accumulation of
misfolded SOD1 into aggregates in isolated mitochon-
drial fractions. A filter trap assay in which proteinaceous
aggregates larger than 220 nm are retained on a cellulose
acetate membrane [45], was performed on homogenates
and isolated mitochondria from spinal cords of pre-
symptomatic (10 week) and early symptomatic
SOD1G93A rats as well as age-matched SOD1WT animals.
Given that this assay is performed in non-denaturing
conditions, we reasoned that the misfolded SOD1
conformational antibodies should retain their specificity.
In agreement with this, misfolded SOD1 antibodies
B8H10, DSE2-3H1 and AMF7-63 preferentially labeled
homogenates of SOD1G93A spinal cords but not controls
(Fig. 5a). Moreover, these three antibodies demonstrated
more intense immunoreactivity for mitochondrial sam-
ples (which were isolated via buoyant density centrifuga-
tion so as to avoid potential co-pelleting of cytoplasmic
aggregates) (Fig. 5a). Furthermore, the formation of
aggregates was disease/age-dependent, with robust label-
ing of homogenates and isolated mitochondria from
early symptomatic animals, but little to no labeling at
10 weeks. Note, the C4F6 antibody detected little to no
aggregates in homogenates or isolated mitochondria at
any age (Fig. 5a), consistent with reports by others that
C4F6 recognizes soluble misfolded SOD1 [31, 46].
Western blots depict SOD1 expression between samples
(Fig. 5b). These results suggest that misfolded SOD1
conformers recognized by B8H10, DSE2-3H1, and
AMF7-63, are components of protein aggregates in both
spinal cord homogenates and are enriched on
mitochondria.
Preferential recognition of demetallated and reduced
recombinant SOD1
To determine if the misfolded SOD1-specific antibodies
have a particular affinity to certain gross perturbations
in SOD1 structure, demetallation, aggregation or reduc-
tion of the intra-molecular disulfide bond, recombinant
wild-type and various SOD1 mutants (G93A, G85R, and
A4V) were spotted onto a nitrocellulose membrane and
blotted with misfolded SOD1 antibodies B8H10 and
AMF7-63 under native conditions. SOD1 proteins that
are properly folded in a native structure have both cop-
per and zinc bound as well as an intact (oxidized) disul-

































symp 17 wks 10 wks 
G93A WT 
early 
symp 17 wks 
Fig. 5 AMF7-63 and B8H10 antibodies detect aggregated misfolded SOD1 in spinal cords. a Size exclusion filter-trap assay of homogenates or
isolated mitochondria from spinal cords of pre-symptomatic (10 week) and early symptomatic SOD1G93A rats or age-matched SOD1WT controls,
blotted for misfolded SOD1-specific antibodies B8H10, DSE2-3H1, AMF7-63 and C4F6. Data is representative of three independent trials. b Homogenates
and isolated mitochondria immunoblotted for SOD1 to verify expression levels. Actin and VDAC serve as loading controls
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to as holo SOD1. Extended incubation of this protein in
ambient conditions can generate misfolded or low levels
of aggregated holo protein [37]. Note, as recombinant
holo SOD1WT aggregates poorly, buffer was applied to
the membrane at that position (dashed box). Protein
lacking both metal cofactors is referred to as apo SOD1.
A reduced apo form of the protein also lacks the crucial
Cys57-Cys146 disulfide bond. For all mutations, both
AMF7-63 and B8H10 had an increased preference for
apo and apo reduced proteins (Fig. 6a). Fully denatured
protein served as a positive control.
To determine if apo SOD1 mutants had a preferential
association with isolated mitochondria, we performed an
in vitro mitochondrial binding assay. Briefly, using sili-
conized tubes, recombinant human SOD1 proteins were
incubated with non-transgenic spinal cord mitochondria,
and after washing away unbound protein, mitochondria
were recovered and analyzed by western blot for the
presence of human SOD1. Recombinant SOD1G93A protein
showed an increased binding to mitochondria compared to
SOD1WT protein. Treatment with ethylenediamine tetraa-
cetic acid (EDTA), to chelate the metal cofactors of SOD1,
resulted in significantly increased binding of SOD1G93A
(Fig. 6b, c). SOD1WT displayed a trend toward increased
binding to mitochondria following treatment with EDTA
(Fig. 6b, c). Treatment with hydrogen peroxide, previ-
ously published to oxidize SOD1 [7], did not signifi-
cantly affect the ability of either recombinant wild-type or
mutant SOD1 to associate with mitochondria (Fig. 6b, c).
Taken together, misfolded SOD1 antibodies B8H10 and
AMF7-63 preferentially detect apo and apo/reduced mis-
folded SOD1, and this form of mutant SOD1 has an in-
creased association with mitochondria in vitro.
Discussion
Misfolded SOD1 specific antibodies recognize distinct
non-native SOD1 conformers
In the literature, there are numerous reports of con-
formational antibodies detecting misfolded SOD1 in
various models, tissues and via different methodologies
yielding sometimes contradictory conclusions and/or
generalizations. We hypothesized that these disparate re-
sults could be attributed to differences in the selectivity
of these reagents for misfolded SOD1, especially if one
considers that “misfolded SOD1” is comprised of more
than one species. Thus, we performed a comprehensive
comparison of six different antibodies in a single genetic
rodent model of ALS using multiple approaches. We
find that misfolded SOD1-specific antibodies partition
























Blot: AMF7-63 Blot: B8H10 
G93A WT A4V G85R G93A WT 
native  denatured
Fig. 6 Misfolded SOD1 specific antibodies show preferential reactivity for demetallated (apo) SOD1. a Recombinant SOD1 proteins (WT, G93A,
G85R and A4V) were produced (i) with its full complement of metals (holo); (ii) with its full complement of metals and incubated so as to
produce low levels of aggregated protein (holo inc); (iii) lacking metals (apo); and (iv) lacking metals and a reduced Cys57-Cys146 disulfide bond
(apo reduced) were spotted onto nitrocellulose and probed for misfolded SOD1 with AMF7-63 (left) and B8H10 (right). b In vitro mitochondrial
binding assay. Recombinant SOD1WT and SOD1G93A were incubated with spinal cord mitochondria from a non-transgenic rat, washed and subjected
to analysis by western blot. Recombinant SOD1 was either left untreated or incubated with EDTA or H2O2 before addition to mitochondria.
c Quantification of b normalized to SOD1G93A binding SOD1WT (white) and SOD1G93A (black). * P < 0.05, ** P < 0.01, n = 5
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D3H5 antibodies predominantly labeling misfolded
SOD1 in motor neurons and numerous puncta within
the neuropil. In contrast, the DSE2-3H1 and AMF7-63
antibodies labeled an extensive fibrillar network localized
to motor neuron cell bodies, axons, and dendrites.
Fibrils are a subset of aggregates composed of β-sheets
observed in many neurodegenerative diseases [47, 48].
Whether SOD1 forms fibrils in SOD1-mediated FALS
cases, remains controversial [16, 49]. However, inclu-
sions found in the spinal cords of mutant SOD1 animal
models contain fibrils that stain positive for Thioflavin
T, a molecule that fluoresces upon binding to β-sheets
[50, 51]. Interestingly, fibrils have the propensity to seed
aggregation in vitro [47], and apo reduced wild-type and
mutant SOD1 readily form fibrils in vitro [51]. More-
over, injection of spinal cord homogenates from mice
overexpressing wild-type or mutant SOD1 into naïve
animal heterozygous YFP-SOD1G85R led to transmission
of motor neuron disease and interestingly, different
abundances and localizations of SOD1 inclusions and fi-
brils. These findings suggest that different SOD1 mu-
tants or non-native species may differ both in their
ability to “seed” further SOD1 aggregates and the prop-
erties of such aggregates [29].
Misfolded SOD1 conformation-specific antibodies may
be especially useful at detecting distinct non-native
forms of SOD1 and aid in dissecting which species con-
tribute to pathology and potentially help to define the
mechanisms implicated. Our work finds that A5C3,
AMF7-63 and B8H10-misfolded SOD1 localize to mito-
chondria whereas as C4F6 does not. Interestingly, al-
though C4F6 and B8H10 were raised against the same
immunogen (full length apo SOD1G93A protein), the lo-
cations of the epitopes are distinct. The C4F6 epitope is
centralized around the G93A mutation (encoded in exon
4) [52], while the B8H10 epitope has been grossly
mapped to the loop region encoded by exon 3 [5]. It is
noteworthy that these two epitopes are located on op-
posite sides (~180°) of the three-dimensional structure
of the SOD1 protein [5]. That only a subset of neurons
carried both epitopes recognized by B8H10 and AMF7-
63 whereas other neurons were labeled with only one of
these antibodies within the same animals strongly sup-
ports that there are indeed multiple non-native mis-
folded SOD1 conformers in vivo. Moreover, we clearly
demonstrate that currently available antibodies represent
powerful tools differentiating these conformers that
could be used to address the impact of distinct mis-
folded SOD1 conformers on neuronal properties.
AMF7-63-reactive misfolded SOD1 correlates with
mitochondrial dysfunction
That several misfolded SOD1-reactive conformers con-
verge at the mitochondria highlights mitochondrial
dysfunction as an important disease mechanism in ALS.
To date, misfolded SOD1 antibodies SEDI [10], DSE2-
3H1 [11, 20], A5C3 [11] B8H10 [13] and AMF7-63 (this
report) detect misfolded SOD1 at the surface of spinal
cord mitochondria. Importantly, in the same spinal cord,
AMF7-63- and B8H10-reactive misfolded SOD1 con-
formers were detected both separately and together on
distinct mitochondrial subpopulations again supporting
potentially distinct impacts of different SOD1 con-
formers on mitochondria.
AMF7-63+ mitochondria have increased size/volume
compared to B8H10+ mitochondria, and exhibit a trend
toward elevated superoxide production. However, separ-
ation into discrete subpopulations, AMF7-63+B8H10−,
AMF7-63+B8H10+, or B8H10+AMF7-63− mitochondria
yielded no significant differences between the groups in
terms of mitochondrial size/volume, although AMF7-63+
and AMF7-63+B8H10+ showed a trend toward in-
creased volume (data not shown). That the AMF7-63+
and B8H10+ mitochondrial subpopulations demon-
strate differences in mitochondrial size/volume sug-
gest that these antibodies recognize distinct misfolded
species that potentially elicit disparate degrees of
damage, with AMF7-63 reactive misfolded SOD1 hav-
ing increased potency. The misfolded SOD1 antibody
DSE2-3H1 detects misfolded SOD1 interacting with
Voltage-dependent anion channel 1 (VDAC1) [20], a
mitochondrial outer membrane protein important for
ion homeostasis [53]. It is reported that recombinant
mutant SOD1 inhibits VDAC1 conductance in a reconsti-
tuted lipid bilayer [20]. Another group, focused on mutant
but not misfolded SOD1, reports that the interaction of
mutant SOD1 with B-cell lymphoma 2 (Bcl-2) and corre-
sponding exposure of the pro-apoptotic BH3 domain is
necessary for Bcl-2 to alter VDAC1 permeability [54]. Our
data does not address whether misfolded SOD1 (DSE2-
3H1 or B8H10-reactive) interacts with Bcl-2. However,
B8H10-reactive misfolded SOD1 and the pro-apoptotic
form of Bcl-2 preferentially accumulate on the same mito-
chondria [13], but this is not indicative of a direct inter-
action. Furthermore, a portion of B8H10+ mitochondria
also contain AMF7-63-reactive SOD1 on their surface.
Therefore, DSE2-3H1-reactive SOD1 could have an in-
creased association with the pro-apoptotic Bcl-2/VDAC1
complex, resulting in altered mitochondrial ion homeosta-
sis. Future knowledge of the interactome of each mis-
folded SOD1 conformer may provide insight into the
possible differences in toxicity elicited by AMF7-63 and
B8H10-reactive misfolded SOD1.
We speculated that DSE2-3H1/AMF7-63-reactive mis-
folded SOD1 may be prone to aggregation, as fibrils are
composed of insoluble, ordered oligomeric chains [55].
However, both B8H10 and AMF7-63 (and DSE2-3H1)
labeled aggregates in spinal cord homogenates and
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isolated mitochondria. Therefore, the increases in mito-
chondrial size/volume elicited by AMF7-63-reactive mis-
folded SOD1 cannot be due solely to its participation in
aggregate formation at the mitochondrial surface. We can-
not exclude the possibility that AMF7-63-reactive mis-
folded SOD1 is included in aggregates of differing size/
properties compared to the B8H10-reactive conformer or
that the solubility of these two forms of misfolded SOD1
may differ so as to account for the increased toxicity. C4F6-
reactive misfolded SOD1 is not detected in aggregates by
this assay, consistent with reports that this antibody recog-
nizes a soluble form of misfolded SOD1 [31, 56].
There is considerable debate over whether SOD1
monomers [17], oligomers [57] or large aggregates [58]
mediate toxicity. A caveat to these studies is they have
focused on cytosolic SOD1. Mitochondria are vulnerable
to proteotoxic stress [59], particularly aggregated pro-
teins [60] and thus, have developed multiple layers of
quality control mechanisms to combat this form of
stress [61]. Mutant SOD1 has been reported to form ag-
gregates in the matrix of brain mitochondria from ALS
animal models [62] and at the surface of mitochondria
of cells over-expressing mutant SOD1 [63]. Whether
these internal- or surface-localized aggregates contain
misfolded SOD1 or cause mitochondrial dysfunction was
not determined. However, several recent studies suggest
that aggregated SOD1 can perturb mitochondrial mem-
brane integrity in vitro [64, 65]. Our results highlight
that multiple misfolded SOD1 conformational antibodies
detect misfolded protein, some of which is found in an
aggregated form, at the surface of mitochondria. Fur-
thermore, the presence of misfolded SOD1 coincides
with disruptions in mitochondrial volume and super-
oxide production, reinforcing that mitochondria are a
bona fide target of SOD1 toxicity.
Demetallated SOD1 is preferentially detected by
misfolded SOD1-specific antibodies AMF7-63 and B8H10
Although broadly considered as a cytosolic protein, a
small portion of SOD1 is localized to the mitochondrial
intermembrane space (IMS) in normal physiological
conditions [66]. In order for SOD1 to be imported into
mitochondria, it must be in its apo reduced form [67].
Given this, a pool of apo SOD1 at the mitochondrial
surface is expected. Interestingly, in our in vitro mito-
chondrial binding assay, apo SOD1 readily associated
with the outer mitochondrial membrane. Import of
mitochondrial substrates is slowed in spinal cord mito-
chondria from SOD1G93A [27], and the regulation of
mutant SOD1s import into mitochondria is altered [68],
therefore apo mutant SOD1 en route to the IMS may be
accumulating at the outer mitochondrial membrane and
disturbing normal mitochondrial physiology. Both
AMF7-63 and B8H10 detected recombinant apo and
apo reduced SOD1 more readily than recombinant holo
SOD1.
Conclusions
Conformational antibodies targeted to misfolded SOD1
show promise not only as therapeutics for ALS, but also
as valuable tools with which to probe the mechanisms of
misfolded SOD1 toxicity. These antibodies have revealed
that multiple non-native species of misfolded SOD1 exist
to contribute to motor neuron degeneration, possibly via
distinct mechanisms [31, 69]. Our study further supports
this premise and highlights that variable potency/toxicity
of different SOD1 species is possible even when only
one SOD1 mutation is present (Fig. 7). Furthermore, we
identify the mitochondria as a target of several of these
misfolded SOD1 conformers. This finding may have
B8H10D3H5 C4F6 AMF7-63A5C3
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Fig. 7 Summary of misfolded SOD1 antibody characteristics. Attributes of various misfolded SOD1 antibodies in spinal cords (presence in
neurons, fibrils and aggregates) and isolated spinal cord mitochondria (outer mitochondrial membrane association, presence in aggregates,
correlation with damage). Epitopes to misfolded SOD1 antibodies used in this study are grossly mapped to the encoding regions. +, positive
finding; −, negative finding; n.d, not determined
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profound implications for therapeutics aimed at neutral-
izing misfolded SOD1.
Additional files
Additional file 1: Figure S1. Misfolded SOD1 specific antibodies do
not label SOD1WT. A) Lumbar spinal cord sections of a symptomatic
SOD1G93A rat and age-matched SOD1WT were labeled with misfolded
SOD1 specific antibodies A5C3, B8H10, C4F6, D3H5, DSE2-3H1, AMF7-63
and SEDI (green). B) No non-specific labeling as determined by IgG
controls (mouse and rabbit), or incubation with secondary antibody
alone, was detected. (PPTX 2948 kb)
Additional file 2: Figure S2. Misfolded SOD1 antibody AMF7-63
specifically identifies mutant SOD1 in spinal cord but not liver from
SOD1G93A rats. The capacity for AMF7-63 to detect misfolded SOD1 in
homogenates or isolated mitochondria from spinal cords and livers was
assayed by immunoprecipitation. Rabbit IgG (IgG) serves as control. Input
is 10 μg of homogenate or isolated mitochondria. From top to bottom
bands correspond to non-specific (ns), human (hSOD1) and rat (rSOD1)
SOD1. (PPTX 562 kb)
Additional file 3: Figure S3. Misfolded SOD1 antibody B8H10
specifically identifies misfolded SOD1 on the surface of isolated
mitochondria from spinal cord but not liver of SOD1G93A rats. A)
Immunolabeling of isolated spinal cord and liver mitochondria with
misfolded SOD1 antibody B8H10 from symptomatic SOD1G93A rats and
controls (age-matched SOD1WT and non-transgenic rats) by flow cytometry.
Misfolded SOD1 positive labeling is determined by comparing to isotype
control (mouse IgG1) of SOD1G93A sample. Percentage of misfolded SOD1+
events is shown for each tissue and genotype in a representative sample. C)
Quantification of B8H10+ events in spinal cord (blue circles) or liver (black
squares) of symptomatic SOD1G93A rats, and age- matched SOD1WT and
non-transgenic rats. Data is represented as percent of misfolded B8H10+
mitochondria (mean ± SEM). *** P < 0.001, n = 3 animals per genotype per
tissue. (PPTX 253 kb)
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